Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge
© 2020 British Society for Immunology..
Solid tumors elicit suppressive T cell responses which impair antigen-presenting cell (APC) functions. Such immune suppression results in uncontrolled tumor growth and mortality. Addressing APC dysfunction, dendritic cell (DC)-mediated anti-tumor vaccination was extensively investigated in both mice and humans. These studies never achieved full resistance to tumor relapse. Herein, we describe a repetitive RM-1 murine tumor rechallenge model for recurrence in humans. Using this newly developed model, we show that priming with tumor antigen-pulsed, Toll-like receptor (TLR)2 ligand-activated DCs elicits a host-protective anti-tumor immune response in C57BL/6 mice. Upon stimulation with the TLR2 ligand peptidoglycan (PGN), the tumor antigen-pulsed DCs induce complete resistance to repetitive tumor challenges. Intra-tumoral injection of PGN reduces tumor growth. The tumor resistance is accompanied by increased expression of interleukin (IL)-27, T-box transcription factor TBX21 (T-bet), IL-12, tumor necrosis factor (TNF)-α and interferon (IFN)-γ, along with heightened cytotoxic T lymphocyte (CTL) functions. Mice primed four times with PGN-stimulated tumor antigen-pulsed DCs remain entirely resistant to repeat challenges with RM-1 tumor cells, suggesting complete prevention of relapse and recurrence of tumor. Adoptive transfer of T cells from these mice, which were fully protected from RM-1 rechallenge, confers anti-tumor immunity to syngeneic naive recipient mice upon RM-1 challenge. These observations indicate that PGN-activated DCs induce robust host-protective anti-tumor T cells that completely resist tumor growth and recurrence.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
|---|---|
| Enthalten in: |
Clinical and experimental immunology - 201(2020), 3 vom: 27. Sept., Seite 279-288 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patidar, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-tumor vaccine |
|---|
| Anmerkungen: |
Date Completed 19.01.2021 Date Revised 03.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cei.13468 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310253950 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310253950 | ||
| 003 | DE-627 | ||
| 005 | 20231225135709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cei.13468 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310253950 | ||
| 035 | |a (NLM)32443171 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patidar, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2021 | ||
| 500 | |a Date Revised 03.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 British Society for Immunology. | ||
| 520 | |a Solid tumors elicit suppressive T cell responses which impair antigen-presenting cell (APC) functions. Such immune suppression results in uncontrolled tumor growth and mortality. Addressing APC dysfunction, dendritic cell (DC)-mediated anti-tumor vaccination was extensively investigated in both mice and humans. These studies never achieved full resistance to tumor relapse. Herein, we describe a repetitive RM-1 murine tumor rechallenge model for recurrence in humans. Using this newly developed model, we show that priming with tumor antigen-pulsed, Toll-like receptor (TLR)2 ligand-activated DCs elicits a host-protective anti-tumor immune response in C57BL/6 mice. Upon stimulation with the TLR2 ligand peptidoglycan (PGN), the tumor antigen-pulsed DCs induce complete resistance to repetitive tumor challenges. Intra-tumoral injection of PGN reduces tumor growth. The tumor resistance is accompanied by increased expression of interleukin (IL)-27, T-box transcription factor TBX21 (T-bet), IL-12, tumor necrosis factor (TNF)-α and interferon (IFN)-γ, along with heightened cytotoxic T lymphocyte (CTL) functions. Mice primed four times with PGN-stimulated tumor antigen-pulsed DCs remain entirely resistant to repeat challenges with RM-1 tumor cells, suggesting complete prevention of relapse and recurrence of tumor. Adoptive transfer of T cells from these mice, which were fully protected from RM-1 rechallenge, confers anti-tumor immunity to syngeneic naive recipient mice upon RM-1 challenge. These observations indicate that PGN-activated DCs induce robust host-protective anti-tumor T cells that completely resist tumor growth and recurrence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Toll-like receptors | |
| 650 | 4 | |a anti-tumor vaccine | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a cytotoxic T cells | |
| 650 | 4 | |a dendritic cells | |
| 650 | 4 | |a peptidoglycan | |
| 650 | 7 | |a Antigens, Neoplasm |2 NLM | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 650 | 7 | |a Peptidoglycan |2 NLM | |
| 650 | 7 | |a Toll-Like Receptor 2 |2 NLM | |
| 700 | 1 | |a Selvaraj, S |e verfasserin |4 aut | |
| 700 | 1 | |a Chauhan, P |e verfasserin |4 aut | |
| 700 | 1 | |a Guzman, C A |e verfasserin |4 aut | |
| 700 | 1 | |a Ebensen, T |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, A |e verfasserin |4 aut | |
| 700 | 1 | |a Chattopadhyay, D |e verfasserin |4 aut | |
| 700 | 1 | |a Saha, B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental immunology |d 1966 |g 201(2020), 3 vom: 27. Sept., Seite 279-288 |w (DE-627)NLM00001527X |x 1365-2249 |7 nnns |
| 773 | 1 | 8 | |g volume:201 |g year:2020 |g number:3 |g day:27 |g month:09 |g pages:279-288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cei.13468 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2020 |e 3 |b 27 |c 09 |h 279-288 | ||